- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03449056
High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease (OPTINEB)
February 11, 2019 updated by: Poitiers University Hospital
High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted for acute respiratory failure.
Literature essentially concerns "de novo" acute hypoxemic failure and the interest of high-flow during take care of chronic obstructive pulmonary disease patients is few studied.
Physiological studies reported potential benefits of high-flow nasal cannula oxygenation in chronic obstructive pulmonary disease patients including dead space clearance and decrease of respiratory, which lead to decrease work of breathing.
As inhaled bronchodilators are part of treatment of chronic obstructive pulmonary disease exacerbation, nebulization could be also provided through high-flow nasal cannula oxygen therapy.
The aim of our study is to determine whether a beta-2 agonist nebulization administered through High-flow nasal cannula is efficient to improve spirometry of patients for admitted hronic obstructive pulmonary disease exacerbation.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jean-Pierre FRAT
- Phone Number: +33549442830
- Email: jean-pierre.frat@chu-poitiers.fr
Study Contact Backup
- Name: nicolas MARJANOVIC
- Email: nicolas.marjanovic@chu-poitiers.fr
Study Locations
-
-
-
Poitiers, France, 86000
- Recruiting
- C.H.U. de Poitiers
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Arterial pH over 7.25,
- Respiratory rate under 35 breaths/mn
- Glasgow Coma Scale equal to 15,
- indication of beta-2 agonist nebulization less than 8 per day (time between two nebulization more than 3 hours),
- NIV sessions spaced more than 6 hours.
Exclusion Criteria:
- Urgent endotracheal intubation;
- Contraindication to beta 2 adrenergic agonist;
- Another organ failure (hemodynamic and neurological instability);
- Cardioselective beta-blocker during treatment of copd exacerbation;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TREATMENT
salbutamol nebulization
|
T2 - T1+1h30: High-nasal flow and salbutamol nebulization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
compare lung functions
Time Frame: baseline-1h30
|
Evolution of Forced Expiratory Volume 1s
|
baseline-1h30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 11, 2019
Primary Completion (ANTICIPATED)
January 1, 2020
Study Completion (ANTICIPATED)
April 1, 2020
Study Registration Dates
First Submitted
January 12, 2018
First Submitted That Met QC Criteria
February 27, 2018
First Posted (ACTUAL)
February 28, 2018
Study Record Updates
Last Update Posted (ACTUAL)
February 12, 2019
Last Update Submitted That Met QC Criteria
February 11, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Albuterol
Other Study ID Numbers
- OPTINEB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on salbutamol
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Canisius-Wilhelmina HospitalRecruitingAsthma in Children | Agents, Anti AsthmaticNetherlands
-
Vastra Gotaland RegionEnrolling by invitationMusculoskeletal Diseases | Neuromuscular Diseases | Centronuclear Myopathy | Nemaline Myopathy | Congenital Myopathy | Myosin Storage MyopathySweden
-
Chiesi Farmaceutici S.p.A.CompletedBronchial AsthmaSpain, Italy, Russian Federation, Ukraine
-
University of Wisconsin, MadisonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedObesity | Pregnancy | PreeclampsiaUnited States
-
Shanghai Ninth People's Hospital Affiliated to...UnknownAdenoid Cystic CarcinomaChina
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.CompletedAsthmaUnited Kingdom
-
The Hospital for Sick ChildrenUniversity Health Network, TorontoRecruiting